Dr. Schmidinger on RCC Therapy Toxicity Management

Manuela Schmidinger, MD
Published: Monday, Oct 21, 2013

Manuela Schmidinger, MD, medical oncologist, Medical University of Vienna, discusses the management of side effects from targeted therapies in renal cell carcinoma (RCC).

Targeted therapies for RCC have plenty of side effects, Schmidinger says. It is crucial that a treating physician pays attention to side effects and takes necessary prophylactic and therapeutic measures.

Otherwise, Schmidinger says, patient's compliance will be reduced over time and physicians are forced to reduce the dose of treatment. Ideally, a patient will stay on treatment at the full dose for as long as possible, as there is a clear dose-response relationship.

Manuela Schmidinger, MD, medical oncologist, Medical University of Vienna, discusses the management of side effects from targeted therapies in renal cell carcinoma (RCC).

Targeted therapies for RCC have plenty of side effects, Schmidinger says. It is crucial that a treating physician pays attention to side effects and takes necessary prophylactic and therapeutic measures.

Otherwise, Schmidinger says, patient's compliance will be reduced over time and physicians are forced to reduce the dose of treatment. Ideally, a patient will stay on treatment at the full dose for as long as possible, as there is a clear dose-response relationship.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x